Wearing-Off Effect Toward the End of Treatment Cycles in Patients With MS Receiving High-Efficacy Disease-Modifying Therapies: Data From Social Media Listening (P3-3.009)

Simple item page
dc.contributor.authorIvan John Clement
dc.contributor.authorJoanne Fielding
dc.contributor.authorMarie Serceau
dc.contributor.authorJanine Robinson
dc.contributor.authorChinmay Deshpande
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T18:58:20Z
dc.date.available2026-03-22T18:58:20Z
dc.date.issued2023
dc.description.abstractTo explore how various stakeholders (patients living with multiple sclerosis [PlwMS], caregivers [CGs], health care practitioners [HCPs], advocacy groups) describe symptoms, timing, coping strategies, and impact on quality of life (QoL) of the wearing-off effect (WOE) while receiving disease-modifying therapies (DMTs; natalizumab, ocrelizumab, ofatumumab, rituximab).
dc.identifier.doi10.1212/wnl.0000000000203254
dc.identifier.urihttps://doi.org/10.1212/wnl.0000000000203254
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/73290
dc.language.isoen
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofNeurology
dc.sourceNovartis (Switzerland)
dc.subjectMedicine
dc.subjectSocial media
dc.subjectActive listening
dc.subjectPhysical therapy
dc.titleWearing-Off Effect Toward the End of Treatment Cycles in Patients With MS Receiving High-Efficacy Disease-Modifying Therapies: Data From Social Media Listening (P3-3.009)
dc.typearticle

Files

Collections

Artículo Científico Publicado